Return to Results

Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators

new search

Trial Conditions
  • Arrhythmia
What is the purpose of this trial?

Implantable cardioverter defibrillators (ICDs) have been developed to treat ventricular tachycardia or fibrillation (abnormal heart rhythms) by electrical shock or by pacing the heart. ICD therapy is established as highly effective for stopping life-threatening arrhythmias, but it does not preclude the use of anti-arrhythmic drugs for prevention and to decrease the frequency of ICD shocks. The safety and effectiveness of oral azimilide dihydrochloride in reducing the frequency of ICD shocks has been investigated previously in a placebo-controlled study in patients with ICDs. These results need to be confirmed in this larger double-blind, placebo-controlled study with approximately 600 patients.

Date & Status


Who can Participate?


18 and older



Inclusion criteria:

- Currently have an ICD implanted

- Have had a documented episode of symptomatic arrhythmias that triggered a spontaneous
ICD shock within 180 days of randomization.

- If the ICD implant is recent, the patient must have had a documented episode of
sustained arrhythmias or cardiac arrest within 42 days before implantation of the ICD

Exclusion criteria:

- have severe heart failure

- have a current diagnosis of psychosis

- use illicit drugs

- abuse alcohol

- if female, are currently breast feeding, or plan to become pregnant during the study

- are currently taking antiarrhythmic drugs or other drugs that prolong the QTc
interval (a measurement taken from the ECG)

- creatinine >2.5 mg/dL (221 mmol/L)

- potassium <4.0 mEq or >5.5 mEq

- have a neutrophil count (ANC) < 100 mL (low count of a type of white blood cell) at
time of randomization

- have 2 or more consecutive QTc values >440 msec

Gender: Both
Steward Physician(s)
  • Jose M Brum, MD
Trial Interventions
  • Azimilide Dihydrochloride
  • placebo
  • Azimilide Dihydrochloride
Physician Researcher

Investigator Name:

  • Jose M Brum, MD

Other Information

Sponsor: Forest Laboratories
Phase: Phase 3
Trial ID: NCT00035490
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions